(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Figuring out Significant Regulations and Guidelines for Organizations - 2The Best Internet based Retailers for Style and Frill
- 3Chinese mega embassy could bring security advantages, says No 10
- 4What we know about Renee Nicole Good, the woman who was killed by an ICE officer in Minneapolis
- 5Opening Monetary Information: Your Exhaustive Manual for Finding out about Individual budget
- Scientists sent a menstrual cup to space. This is how it went
- 5 Family SUVs for 2024: Which One Accommodates Your Family's Needs\uff1f
- Vote in favor of your Number one Kind of Gems
- As tetanus vaccination rates decline, doctors worry about rising case numbers
- From Squid Game to Your Party! Six Entertaining Test Games That Will Have You in Join
- Figure out How to Pick the Right Dental specialist for Your Dental Inserts
- Affordable Care Act enrollment is slightly ahead of last year, despite expiring subsidies
- Vote in favor of your #1 Kind of Cap
- 5 Eating routine Well disposed Snacks to Keep You Fulfilled
